Skip to main content
Erschienen in: Tumor Biology 3/2012

01.06.2012 | Research Article

Clinical and molecular detection of inherited colorectal cancers in northeast Italy

A first prospective study of incidence of Lynch syndrome and MUTYH-related colorectal cancer in Italy

verfasst von: E. Urso, M. Agostini, S. Pucciarelli, M. Rugge, R. Bertorelle, I. Maretto, C. Bedin, E. D’Angelo, C. Mescoli, M. Zorzi, A. Viel, G. Bruttocao, B. Ferraro, F. Erroi, P. Contin, G. L. De Salvo, D. Nitti

Erschienen in: Tumor Biology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

The reported incidence of hereditary colorectal cancers (CRCs) is widely variable. The principal aim of the study was to prospectively evaluate the incidence of familial CRCs in a region of northern Italy using a standardized method. Consecutive CRC patients were prospectively enrolled from October 2002 to December 2003. Patients underwent a structured family history, the microsatellite instability (MSI) test and a screen for MUTYH mutations. Following family history patients were classified as belonging to high, moderate and mild risk families. Immunohistochemistry for MLH1, MSH2, MSH6 and PMS2 proteins and investigation for MLH1/MSH2 mutations, for MLH1 promoter methylation and for the V600E hotspot BRAF mutation were performed in high MSI (MSI-H) cases. Of the 430 patients enrolled, 17 (4%) were high risk [4 hereditary non-polyposis colorectal cancer (HNPCC), 12 suspected HNPCC and 1 MUTYH-associated adenomatous polyposis coli (MAP)], 53 moderate risk and 360 mild risk cases. The MSI test was performed on 393 tumours, and 46 (12%) of them showed MSI-H. In these patients, one MLH1 pathogenetic mutations and two MSH2 pathogenetic mutations were found. Thirty-two (70%) MSI-H cases demonstrated MLH1 methylation and/or BRAF mutation: None of them showed MLH1/MSH2 mutation. Two biallelic germline MUTYH mutations were found, one with clinical features of MAP. A strong family history of CRC was present in 4% of the enrolled cases; incidence of MLH1/MSH2 or MUTHY mutations was 1.3% and of MSI-H phenotype was 12%. MLH1 methylation and BRAF mutation can exclude 70% of MSI-H cases from gene sequencing.
Literatur
1.
Zurück zum Zitat Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–34.PubMedCrossRef Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–34.PubMedCrossRef
2.
Zurück zum Zitat Vasen HFA, Mecklin J-P, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34:424–5.PubMedCrossRef Vasen HFA, Mecklin J-P, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34:424–5.PubMedCrossRef
3.
Zurück zum Zitat Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology. 1999;116:1453–6.PubMedCrossRef Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology. 1999;116:1453–6.PubMedCrossRef
5.
Zurück zum Zitat Syngal S, Fox EA, Eng C, et al. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet. 2000;37:641–5.PubMedCrossRef Syngal S, Fox EA, Eng C, et al. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet. 2000;37:641–5.PubMedCrossRef
6.
Zurück zum Zitat Boland CR, Koi M, Chang DK, Carethers JM. The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. Fam Cancer. 2008;7:41–52.PubMedCrossRef Boland CR, Koi M, Chang DK, Carethers JM. The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. Fam Cancer. 2008;7:41–52.PubMedCrossRef
7.
Zurück zum Zitat Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352:1851–60.PubMedCrossRef Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352:1851–60.PubMedCrossRef
8.
Zurück zum Zitat Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991;66:580–600.CrossRef Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991;66:580–600.CrossRef
9.
Zurück zum Zitat Knudsen AL, Bisgaard L, Bülow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Familial cancer. 2003;2:43–55.PubMedCrossRef Knudsen AL, Bisgaard L, Bülow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Familial cancer. 2003;2:43–55.PubMedCrossRef
10.
Zurück zum Zitat Sampson JR, Jones N. MUTYH-associated polyposis. Best Pract Res Clin Gastroenterol. 2009;23:209–18.PubMedCrossRef Sampson JR, Jones N. MUTYH-associated polyposis. Best Pract Res Clin Gastroenterol. 2009;23:209–18.PubMedCrossRef
11.
Zurück zum Zitat Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MUTYH associated with somatic G:C?T:A mutations in colorectal tumors. Nat Genet. 2002;30:227–32.PubMedCrossRef Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MUTYH associated with somatic G:C?T:A mutations in colorectal tumors. Nat Genet. 2002;30:227–32.PubMedCrossRef
12.
Zurück zum Zitat Halford SE, Rowan AJ, Lipton L, et al. Germline mutations but not somatic changes at the MUTYH locus contribute to the pathogenesis of unselected colorectal cancers. Am J Pathol. 2003;162:1545–8.PubMedCrossRef Halford SE, Rowan AJ, Lipton L, et al. Germline mutations but not somatic changes at the MUTYH locus contribute to the pathogenesis of unselected colorectal cancers. Am J Pathol. 2003;162:1545–8.PubMedCrossRef
13.
Zurück zum Zitat Park JG, Vasen HF, Park KJ, et al. Suspected hereditary nonpolyposis colorectal cancer: International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) criteria and results of genetic diagnosis. Dis Colon Rectum. 1999;42:710–5.PubMedCrossRef Park JG, Vasen HF, Park KJ, et al. Suspected hereditary nonpolyposis colorectal cancer: International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) criteria and results of genetic diagnosis. Dis Colon Rectum. 1999;42:710–5.PubMedCrossRef
14.
Zurück zum Zitat Boland CR, Thibodeau SN, Hamilton SR, et al. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248–57.PubMed Boland CR, Thibodeau SN, Hamilton SR, et al. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248–57.PubMed
15.
Zurück zum Zitat Agostini M, Enzo MV, Morandi L, et al. A ten markers panel provides a more accurate and complete microsatellite instability analysis in mismatch repair-deficient colorectal tumors. Cancer Biomarkers. 2010;6:49–61.PubMed Agostini M, Enzo MV, Morandi L, et al. A ten markers panel provides a more accurate and complete microsatellite instability analysis in mismatch repair-deficient colorectal tumors. Cancer Biomarkers. 2010;6:49–61.PubMed
16.
Zurück zum Zitat Menigatti M, Di Gregorio C, Borghi F, et al. Methylation pattern of different regions of the MLH1 promoter and silencing of gene expression in hereditary and sporadic colorectal cancer. Genes Chromosomes Cancer. 2001;31:357–61.PubMedCrossRef Menigatti M, Di Gregorio C, Borghi F, et al. Methylation pattern of different regions of the MLH1 promoter and silencing of gene expression in hereditary and sporadic colorectal cancer. Genes Chromosomes Cancer. 2001;31:357–61.PubMedCrossRef
17.
Zurück zum Zitat Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934. 69.PubMedCrossRef Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934. 69.PubMedCrossRef
18.
Zurück zum Zitat Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10:191–5.PubMedCrossRef Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10:191–5.PubMedCrossRef
19.
Zurück zum Zitat Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci. 1996;93:9821–6.PubMedCrossRef Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci. 1996;93:9821–6.PubMedCrossRef
20.
Zurück zum Zitat Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002;20(4):1043–8.PubMedCrossRef Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002;20(4):1043–8.PubMedCrossRef
21.
Zurück zum Zitat Agostini M, Tibiletti Mg, Lucci-Cordisco E, et al. Two PMS2 mutations in a Turcot syndrome family with small bowel cancers. Am J Gastroenterol. 2005;100(8):1886–91.PubMedCrossRef Agostini M, Tibiletti Mg, Lucci-Cordisco E, et al. Two PMS2 mutations in a Turcot syndrome family with small bowel cancers. Am J Gastroenterol. 2005;100(8):1886–91.PubMedCrossRef
22.
Zurück zum Zitat Nascimbeni R, Pucciarelli S, Di Lorenzo D, et al. Rectum-sparing surgery may be appropriate for biallelic MutYH-associated polyposis. Disease and Colon Rectum. 2010;53(12):1670–5.CrossRef Nascimbeni R, Pucciarelli S, Di Lorenzo D, et al. Rectum-sparing surgery may be appropriate for biallelic MutYH-associated polyposis. Disease and Colon Rectum. 2010;53(12):1670–5.CrossRef
23.
Zurück zum Zitat Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30:e57.PubMedCrossRef Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30:e57.PubMedCrossRef
24.
Zurück zum Zitat Pastrello C, Pin E, Marroni F, Bedin C, et al. Integrated analysis of unclassified variants in mismatch repair genes. Genet Med. 2011;13(2):115–24.PubMedCrossRef Pastrello C, Pin E, Marroni F, Bedin C, et al. Integrated analysis of unclassified variants in mismatch repair genes. Genet Med. 2011;13(2):115–24.PubMedCrossRef
25.
Zurück zum Zitat Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.PubMedCrossRef Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.PubMedCrossRef
26.
Zurück zum Zitat Gismondi V, Meta M, Bonelli L, et al. Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MUTYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas. Int J Cancer. 2004;109:680–4.PubMedCrossRef Gismondi V, Meta M, Bonelli L, et al. Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MUTYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas. Int J Cancer. 2004;109:680–4.PubMedCrossRef
27.
Zurück zum Zitat Avezzù A, Agostini M, Pucciarelli S, et al. The role of MUTYH gene in genetic predisposition to colorectal cancer: another piece of the puzzle. Cancer Letter. 2008;268:308–13.CrossRef Avezzù A, Agostini M, Pucciarelli S, et al. The role of MUTYH gene in genetic predisposition to colorectal cancer: another piece of the puzzle. Cancer Letter. 2008;268:308–13.CrossRef
28.
Zurück zum Zitat Evans DGR, Walsh JJ, Robinson C, et al. Incidence of hereditary non polyposis colorectal cancer in a population-based study of 1137 consecutive cases of colorectal cancer. Br J Surg. 1997;84:1281–5.PubMedCrossRef Evans DGR, Walsh JJ, Robinson C, et al. Incidence of hereditary non polyposis colorectal cancer in a population-based study of 1137 consecutive cases of colorectal cancer. Br J Surg. 1997;84:1281–5.PubMedCrossRef
29.
Zurück zum Zitat Katballe N, Christensen M, Wikman FP, et al. Frequency of hereditary non polyposis colorectal cancer in Danish colorectal cancer patients. Gut. 2002;50:43–51.PubMedCrossRef Katballe N, Christensen M, Wikman FP, et al. Frequency of hereditary non polyposis colorectal cancer in Danish colorectal cancer patients. Gut. 2002;50:43–51.PubMedCrossRef
30.
Zurück zum Zitat Peel DJ, Ziogas A, Fox EA, et al. Characterization of hereditary non polyposis colorectal cancer families from a population based series of cases. J Natl Cancer Inst. 2000;92:1517–22.PubMedCrossRef Peel DJ, Ziogas A, Fox EA, et al. Characterization of hereditary non polyposis colorectal cancer families from a population based series of cases. J Natl Cancer Inst. 2000;92:1517–22.PubMedCrossRef
31.
Zurück zum Zitat Ruo L, Cellini C, La-Calle Jr JP, Murray M, Thaler HT, Quan SH, et al. Limitations of family cancer history assessment at initial surgical consultation. Dis Colon Rectum. 2001;44:98–103.PubMedCrossRef Ruo L, Cellini C, La-Calle Jr JP, Murray M, Thaler HT, Quan SH, et al. Limitations of family cancer history assessment at initial surgical consultation. Dis Colon Rectum. 2001;44:98–103.PubMedCrossRef
32.
Zurück zum Zitat Percesepe A, Borghi F, Menigatti M, et al. Molecular screening for hereditary nonpolyposis colorectal cancer: a prospective, population based study. J Clin Oncol. 2001;19:3944–50.PubMed Percesepe A, Borghi F, Menigatti M, et al. Molecular screening for hereditary nonpolyposis colorectal cancer: a prospective, population based study. J Clin Oncol. 2001;19:3944–50.PubMed
33.
Zurück zum Zitat Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary colorectal cancer and the feasibility of molecular screening for the disease. NEJM. 1998;338:1481–7.PubMedCrossRef Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary colorectal cancer and the feasibility of molecular screening for the disease. NEJM. 1998;338:1481–7.PubMedCrossRef
34.
Zurück zum Zitat Salovaara R, Loukola A, Kristo P, et al. Population based molecular detection of hereditary non polyposys colorectal cancer. J Clin Oncol. 2000;18:2193–200.PubMed Salovaara R, Loukola A, Kristo P, et al. Population based molecular detection of hereditary non polyposys colorectal cancer. J Clin Oncol. 2000;18:2193–200.PubMed
35.
Zurück zum Zitat Piñol V, Castells A, Andreu M, et al, for the Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005;293:1986–94. Piñol V, Castells A, Andreu M, et al, for the Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005;293:1986–94.
36.
Zurück zum Zitat Lagerstedt Robinson K, Liu T, Vandrovcova J, et al. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst. 2007;99:291–9.PubMedCrossRef Lagerstedt Robinson K, Liu T, Vandrovcova J, et al. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst. 2007;99:291–9.PubMedCrossRef
37.
Zurück zum Zitat Balaguer F, Castellví-Bel S, Castells A, et al. Gastrointestinal oncology group of the Spanish gastroenterological association. Identification of MUTYH mutation carriers in colorectal cancer: a multicenter, case–control, population-based study. Clin Gastroenterol Hepatol. 2007;5:379–87.PubMedCrossRef Balaguer F, Castellví-Bel S, Castells A, et al. Gastrointestinal oncology group of the Spanish gastroenterological association. Identification of MUTYH mutation carriers in colorectal cancer: a multicenter, case–control, population-based study. Clin Gastroenterol Hepatol. 2007;5:379–87.PubMedCrossRef
38.
Zurück zum Zitat Croitoru ME, Cleary SP, Di Nicola N, et al. Association between biallelic and monoallelic germline MUTYH gene mutations and colorectal cancer risk. J Natl Cancer Inst. 2004;96(21):1631–4.PubMedCrossRef Croitoru ME, Cleary SP, Di Nicola N, et al. Association between biallelic and monoallelic germline MUTYH gene mutations and colorectal cancer risk. J Natl Cancer Inst. 2004;96(21):1631–4.PubMedCrossRef
39.
Zurück zum Zitat Kim IJ, Ku JL, Kang HC, et al. Mutational analysis of OGG1, MUTYH, MTH1 in FAP, HNPCC and sporadic colorectal cancer patients: R154H OGG1 polymorphism is associated with sporadic colorectal cancer patients. Hum Genet. 2004;115:498–503.PubMedCrossRef Kim IJ, Ku JL, Kang HC, et al. Mutational analysis of OGG1, MUTYH, MTH1 in FAP, HNPCC and sporadic colorectal cancer patients: R154H OGG1 polymorphism is associated with sporadic colorectal cancer patients. Hum Genet. 2004;115:498–503.PubMedCrossRef
40.
Zurück zum Zitat Görgens H, Krüger S, Kuhlisch E, Pagenstecher C, Höhl R, Schackert HK, et al. Microsatellite stable colorectal cancers in clinically suspected hereditary nonpolyposis colorectal cancer patients without vertical transmission of disease are unlikely to be caused by biallelic germline mutations in MUTYH. J Mol Diagn. 2006;8:178–82.PubMedCrossRef Görgens H, Krüger S, Kuhlisch E, Pagenstecher C, Höhl R, Schackert HK, et al. Microsatellite stable colorectal cancers in clinically suspected hereditary nonpolyposis colorectal cancer patients without vertical transmission of disease are unlikely to be caused by biallelic germline mutations in MUTYH. J Mol Diagn. 2006;8:178–82.PubMedCrossRef
41.
Zurück zum Zitat Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA. 2005;293:1979–85.PubMedCrossRef Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA. 2005;293:1979–85.PubMedCrossRef
42.
Zurück zum Zitat Salovaara R, Loukola A, Kristo P, et al. Population based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2002;18:2193–200. Salovaara R, Loukola A, Kristo P, et al. Population based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2002;18:2193–200.
43.
Zurück zum Zitat Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.PubMedCrossRef Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.PubMedCrossRef
44.
Zurück zum Zitat Carethers JM. Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer. Gut. 2006;55:1819.PubMedCrossRef Carethers JM. Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer. Gut. 2006;55:1819.PubMedCrossRef
45.
Zurück zum Zitat Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis. 2008;29:673–80.PubMedCrossRef Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis. 2008;29:673–80.PubMedCrossRef
46.
Zurück zum Zitat Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet. 2004;41:663–7.CrossRef Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet. 2004;41:663–7.CrossRef
Metadaten
Titel
Clinical and molecular detection of inherited colorectal cancers in northeast Italy
A first prospective study of incidence of Lynch syndrome and MUTYH-related colorectal cancer in Italy
verfasst von
E. Urso
M. Agostini
S. Pucciarelli
M. Rugge
R. Bertorelle
I. Maretto
C. Bedin
E. D’Angelo
C. Mescoli
M. Zorzi
A. Viel
G. Bruttocao
B. Ferraro
F. Erroi
P. Contin
G. L. De Salvo
D. Nitti
Publikationsdatum
01.06.2012
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 3/2012
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0312-0

Weitere Artikel der Ausgabe 3/2012

Tumor Biology 3/2012 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.